Letter | Published:

Some Pharmacological Properties of a New Adrenergic β-Receptor Antagonist

Naturevolume 212pages8890 (1966) | Download Citation



SEVERAL compounds have now been described as adrenergic β-receptor antagonists including dichloroisoprenaline1 pronethalol (‘Alderlin’)2, propranolol (‘Inderal’)3, MJ 1999 (ref. 4), and INPEA5. Propranolol is about ten times more active than the other compounds in blocking the inotropic and chronotropic actions of catecholamines6. Studies with pronethalol and propranolol have shown that adrenergic β-receptor antagonists are valuable in the treatment of various clinical disorders7–11. The use of pronethalol was restricted when it was shown to be a potential carcinogenic agent in mice12; propranolol is devoid of this action13. This communication describes some of the pharmacological properties of a new adrenergic β-receptor antagonist 1-isopropylamino-3-(3-tolyloxy)-2-propanol hydrochloride (‘I.C.I. 45,763’), selected from a series of phenoxypropanolamines synthesized by Crowther Smith and Wood14.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Powell, C. E., and Slater, I. H., J. Pharmacol., 122, 480 (1958).

  2. 2

    Black, J. W., and Stephenson, J. S., Lancet, ii, 311 (1962).

  3. 3

    Black, J. W., Crowther, A. F., Shanks, R. G., Smith, L. H., and Dornhorst, A. C., Lancet, i, 1080 (1964).

  4. 4

    Lish, P. M., Weikel, J. H., and Dungan, K. W., J. Pharmacol., 149, 161 (1965).

  5. 5

    Teotino, U. M., Polo Friz, L., Streis, G., and Della Bella, D., J. Pharm. Pharmacol., 15, 26 (1963).

  6. 6

    Shanks, R. G., Biochem. Pharmacol. (in the press).

  7. 7

    Stock, J. P. P., and Dale, N., Brit. Med. J., ii, 1230 (1963).

  8. 8

    Rowlands, D. J., Howitt, G., and Markman, P., Brit. Med. J., i, 891 (1965).

  9. 9

    Hamer, J., Grandjean, T., Melendez, L., and Sowton, G. E., Brit. Med. J., ii, 720 (1964).

  10. 10

    Gillam, P. M. S., and Prichard, B. N. C., Brit. Med. J., ii, 337 (1965).

  11. 11

    Goodwin, J. F., Shah, P. M., Oakley, C. M., Cohen, J., Yipintsoi, T., and Pocock, W., Ciba Found. Symp., Cardiomyopathies, 189 (1964).

  12. 12

    Alcock, S. J., and Bond, P. A., Proc. Europ. Soc. Study Drug Toxic., 4, 30 (1965).

  13. 13

    Tucker, M. J., Alcock, S. J., and Baker, S. B. de C., Brit. Med. J., ii, 363 (1965).

  14. 14

    Crowther, A. F., Smith, L. H., and Wood, T. M., U.K. Patent Application No. 46740/62, Belgian Patent No. 641,133.

  15. 15

    Black, J. W., Duncan, W. A. M., and Shanks, R. G., Brit. J. Pharmacol., 25, 577 (1965).

  16. 16

    Orlans, F. B. H., Finger, K. F., and Brodie, B. B., J. Pharmacol., 128, 131 (1960).

  17. 17

    Levy, B., and Ahlquist, R. P., J. Pharmacol., 133, 202 (1961).

  18. 18

    Stock, K., and Westerman, E., Biochem. Pharmacol., 14, 227 (1965).

  19. 19

    Baker, S. B. de C. (personal communication).

Download references

Author information


  1. Pharmaceuticals Division, Imperial Chemical Industries, Ltd., Alderley Park, Macclesfield, Cheshire

    • R. G. SHANKS
    •  & T. M. WOOD
  2. Medical Unit, St. George's Hospital, London, S.W.1.

    •  & M. L. CLARK


  1. Search for R. G. SHANKS in:

  2. Search for T. M. WOOD in:

  3. Search for A. C. DORNHORST in:

  4. Search for M. L. CLARK in:

About this article

Publication history

Issue Date



Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.